Publicaciones en colaboración con investigadores/as de Hospital Universitari Germans Trias i Pujol (15)

2023

  1. Author Correction: BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer (Scientific Reports, (2015), 5, 1, (17499), 10.1038/srep17499)

    Scientific Reports

  2. Immunogenicity of COVID-19 vaccines in lung cancer patients

    Lung Cancer, Vol. 184

2022

  1. Seroprevalence and immunological memory against SARS-CoV-2 in lung cancer patients: the SOLID study

    Translational Lung Cancer Research, Vol. 11, Núm. 1, pp. 53-63

2019

  1. Association of PALB2 Messenger RNA Expression with Platinum-Docetaxel Efficacy in Advanced Non–Small Cell Lung Cancer

    Journal of Thoracic Oncology, Vol. 14, Núm. 2, pp. 304-310

2017

  1. Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC

    Journal of the National Cancer Institute, Vol. 109, Núm. 9

2015

  1. BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer

    Scientific Reports, Vol. 5

2014

  1. Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: The BRCA1-RAP80 Expression Customization (BREC) studies

    Annals of Oncology, Vol. 25, Núm. 11, pp. 2147-2155

2013

  1. Adjuvant therapy with bemiparin in patients with limited-stage small cell lung cancer: Results from the ABEL study

    Thrombosis Research, Vol. 132, Núm. 6, pp. 666-670

2010

  1. Phase I/II and pharmacokinetic study of intravenous vinflunine in combination with cisplatin for the treatment of chemonaive patients with advanced non-small-cell lung cancer

    Clinical Lung Cancer, Vol. 11, Núm. 2, pp. 105-113

2007

  1. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: A phase III trial in non-small-cell lung cancer

    Journal of Clinical Oncology, Vol. 25, Núm. 19, pp. 2747-2754

2006

  1. The place of targeted therapies in the management of non-small cell bronchial carcinoma: Molecular markers as predictors of tumor response and survival in lung cancer

    Revue des Maladies Respiratoires, Vol. 23, Núm. 5 C3

2004

  1. Single nucleotide polymorphisms and outcome in docetaxel - Cisplatin-treated advanced non-small-cell lung cancer

    Annals of Oncology, Vol. 15, Núm. 8, pp. 1194-1203

2003

  1. Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: A Spanish Lung Cancer Group phase III randomized trial

    Journal of Clinical Oncology, Vol. 21, Núm. 17, pp. 3207-3213

  2. Influence of genetic markers on survival in non-small cell lung cancer

    Drugs of Today, Vol. 39, Núm. 10, pp. 775-786

  3. Three-week schedule of irinotecan and cisplatin in advanced non-small cell lung cancer: A multicentre phase II study

    Lung Cancer, Vol. 39, Núm. 2, pp. 201-207